Can I read Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial on EtoBox?

Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial by Cheng Xu, Guan-Qun Zhou,Wen-Fei Li, ..., Liang-Fang Shen,Ying Sun, Jun Ma is a book available to read on EtoBox.

What is Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial about?

Cancer Cell, 43 (2025) 925-940. doi:10.1016/j.ccell.2025.01.014SUMMARYSevere toxicities caused by concurrent cisplatin are a critical problem in nasopharyngeal carcinoma (NPC)treatment. In this phase 2 multicenter PLATINUM trial (NCT03984357), we recruited 152 NPC patients whoreceived 12-cycle nivolumab plus induction chemotherapy and radiotherapy without concurrent cisplatin. After a median follow-up of 43 months, the 3-year failure-free survival (FFS) was 88.5% (95% confidence interval[CI], 83.4%–93.8%) and the 3-year overall survival was 97.9%. An early clearance of Epstein-Barr virus (EBV)DNA after induction-phase treatment was associated with FFS benefit. Sixty (40.2%) and eight (5.2%) patients had acute and late grade 3–4 adverse events (AEs), respectively. Most patients had good toleranceto AE-associated frequency (68.0%–96.7%), severity (56.0%–98.6%), and interference (58.0%–98.0%);86.7%–100.0% of quality-of-life domains showed either no clinically meaningful deterioration or a rapid recovery. Nivolumab plus induction chemotherapy and radiotherapy demonstrated efficacious anti-tumor activity, low toxicity, and favorable tolerability and quality-of-life for NPC patients.

Author

Cheng Xu, Guan-Qun Zhou,Wen-Fei Li, ..., Liang-Fang Shen,Ying Sun, Jun Ma

Publisher

The Author(s)

Published

2025

Language

EN